Targeting the androgen receptor in triple negative breast cancer

Start Year: 2013
Finish Year: 2016
Chief Investigator: Professor Wayne Tilley
Grant Type: Cancer Australia Priority Driven Collaborative Cancer Research Scheme(PdCCRS)
Institution: The University of Adelaide

Triple negative is a term used to describe types of breast cancer that do not have any of three receptors commonly found on breast cancer cells: oestrogen receptors, progesterone receptors and human epidermal growth factor receptor (HER2].

Generally, these types of breast cancers that often occur in younger women do not respond well to current targeted therapies, are more aggressive, and are associated with higher mortality rates.

Recently, clinical attention has focused on targeting the androgen receptor to treat triple negative breast cancer. While this may be a promising approach, we need to know more about how androgens act in these cancers.

This project will determine which triple negative breast cancers are most likely to respond to therapeutic approaches that target androgen receptor.

Co-funded by NBCF and Cancer Australia.

Triple negative is a term used to describe types of breast cancer that do not have any of three receptors commonly found on breast cancer cells: oestrogen receptors, progesterone receptors and human epidermal growth factor receptor (HER2].

Generally, these types of breast cancers that often occur in younger women do not respond well to current targeted therapies, are more aggressive, and are associated with higher mortality rates.

Recently, clinical attention has focused on targeting the androgen receptor to treat triple negative breast cancer. While this may be a promising approach, we need to know more about how androgens act in these cancers.

This project will determine which triple negative breast cancers are most likely to respond to therapeutic approaches that target androgen receptor.

Co-funded by NBCF and Cancer Australia.